SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
Ella Day | July 8, 2025 | News story | Medical Communications, Research and Development | Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use in Scotland. This offers a new treatment option for postmenopausal women at high risk of fracture.
Osteoporosis is a progressive condition causing fragile bones and fractures. Hip fractures alone are responsible for around 50% of fracture-related deaths in women. Many patients remain undiagnosed or untreated, and fractures often recur before osteoporosis is identified.
Eladynos is an anabolic therapy and works by stimulating new bone formation to strengthen bones and reduce the risk of fracture. Clinical trials, including the ACTIVE and ACTIVExtend studies, showed significant reductions in vertebral fractures and consistent protection when followed by bisphosphonate therapy. It is a once-daily injection and recommended for up to 18 months of treatment.
Tina Backhouse, UK general manager at Theramex, stated: “With women at a five times greater risk of osteoporosis than men, I am thrilled that we are able to expand access further across the UK and bring this treatment to women in Scotland.”
The approval follows previous guidance from NICE and means that, for the first time, women in Scotland will have NHS access to this treatment. However, charities warn that gaps in care remain, with many high-risk patients still missing out on timely diagnosis and treatment.
Ella Day
8/7/25
Related Content
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
By Sabina Syed and Ewan Maule The Cardiovascular Disease Modern Service Framework1(CVD MSF) begins with a …
Manchester launches nurse-led clinic to improve kidney transplant outcomes
Manchester University NHS Foundation Trust has launched a specialist nurse-led clinic designed to provide more …
EMA selects TrialAssure anonymisation platform for clinical trial documents
TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …
